Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16005763 | 1.00 | L3MBTL1 (0.34) | L3MBTL1KDM4ECYP3A4ALDH1A1SMN1; SMN2 | |
| SCHEMBL4203563 | 0.90 | CYP3A4 (0.35) | L3MBTL1KDM4ECYP3A4PIN1TP53 | |
| SCHEMBL3407981 | 0.89 | KDM4E (0.35) | L3MBTL1KDM4ECYP3A4TP53GAA | |
| SCHEMBL3410149 | 0.85 | KDM4E (0.30) | KDM4E | |
| SCHEMBL5047855 | 0.85 | KDM4E (0.30) | KDM4E | |
| SCHEMBL16005762 | 0.84 | MAPT (0.33) | L3MBTL1KDM4EGAA | |
| SCHEMBL4203147 | 0.84 | MAPT (0.33) | L3MBTL1KDM4EGAA | |
| SCHEMBL3414070 | 0.83 | KDM4E (0.30) | KDM4E | |
| SCHEMBL2969739 | 0.78 | L3MBTL1 (0.32) | L3MBTL1KDM4ETP53 | |
| SCHEMBL16005779 | 0.75 | SMN1; SMN2 (0.31) | L3MBTL1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036483-A1 | QUINOLINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-02-05 | — | — | US | claimed |
| US-7446114-B2 | Quinolinone compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2008-11-04 | — | — | US | claimed |
| EP-1871772-A1 | QUINOLINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | Theravance, Inc. (US) | 2008-01-02 | — | — | EP | claimed |
| WO-2006094063-A1 | QUINOLINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2006-09-08 | — | — | WO | claimed |
| US-20060199839-A1 | Quinolinone compounds as 5-HT4 receptor agonists | THERAVANCE, INC. | 2006-09-07 | — | — | US | claimed |
| EP-1871772-B1 | QUINOLINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE INC (US) | 2014-09-10 | — | — | EP | disclosed |
| US-20090036483-A1 | QUINOLINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-02-05 | — | — | US | disclosed |
| US-7446114-B2 | Quinolinone compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2008-11-04 | — | — | US | disclosed |
| US-20060199839-A1 | Quinolinone compounds as 5-HT4 receptor agonists | THERAVANCE, INC. | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036483-A1 | QUINOLINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1A | L3MBTL1 4797/4885KDM4E 1499/4885CYP3A4 191/4885 |
| US-20060199839-A1 | Quinolinone compounds as 5-HT4 receptor agonists | HTR4, HTR5A, HTR1A | L3MBTL1 4797/4885KDM4E 1499/4885CYP3A4 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.